Inflammatory Breast Cancer Clinical Trial
Official title:
Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia
One form of breast cancer, known as inflammatory breast cancer (IBC), is characterized by
diffuse erythema (redness) and edema (peau d'orange) of the breast. This type of cancer is
aggressive and poorly understood. It is rare in the United States (about 4 percent of cases),
but more common in Egypt and Tunisia (up to 23 percent of cases). Conducting a case-control
study of IBC is complicated by several factors, including the lack of standardized criteria
for IBC. In addition, collecting pre-chemotherapy tissue and blood samples from IBC patients
is difficult because treatment begins immediately after diagnosis.
In this pilot study, the National Cancer Institute will collaborate with two major cancer
centers and two hospitals (in Egypt and Tunisia) to determine the feasibility of a
case-control study of IBC. The study will assess the number and characteristics of IBC cases,
the feasibility of identifying cases at diagnosis, and the availability of control subjects;
will collect frozen pre-treatment tumor tissue from five IBC cases to determine whether RNA
isolation is possible; will obtain digital photographs of the breasts of IBC cases; and will
demonstrate collaboration between the institutions and personnel involved in the study. The
study will last for approximately one year.
Participating hospitals will identify IBC cases. Consenting patients will undergo a breast
examination in which the examining surgeon will complete an Initial Examination Form (IEF).
Digital photographs of the breasts (but not face) will be taken and linked to the study ID
number. Tissue examination results will be entered into the IEF. For five selected cases,
additional pre-treatment tumor tissue will be collected and frozen.
This pilot study will assess the availability of controls for a case-control study by
investigating the number and type of admissions to the Ear, Nose, and Throat and
Ophthalmology Departments at participating hospitals during 2000-2003, using computerized
records.
Breast cancer characterized by diffuse erythema and edema, or peau d'orange, of the breast
(inflammatory breast cancer (IBC)) is rare, particularly aggressive, and poorly understood.
The extent of redness and edema or peau d'orange, of the breast required for a diagnosis of
IBC has not been standardized. According to the most recent American Joint Committee on
Cancer (AJCC) definition of inflammatory breast cancer, the signs of redness and edema or
peau d'orange, should cover the majority of the breast, and should have arisen quickly.
Breast cancers with redness and edema or peau d'orange, account for approximately 4 percent
of breast cancers in the United States, but up to 23 percent of breast cancers in Egypt and
Tunisia.
The proposed pilot study will determine the feasibility of conducting a case-control study of
inflammatory breast cancer in collaboration with the National Cancer Institute-Cairo, Egypt,
and the Institut Salah Azaiz, Tunis, Tunisia, the major cancer centers in Egypt and Tunisia,
and Cairo University Hospital and Charles Nicolle Hospital, affiliated general hospitals from
which controls will be selected. Currently, neither case study hospital collects data on the
number of inflammatory breast cancer cases meeting the AJCC definition which will be used for
the proposed case-control study. In addition, the geographic distribution of IBC cases at the
two study hospitals (knowledge of which is necessary for the selection of appropriate
controls) is unknown.
The goals of the pilot study are to assess the feasibility of the following critical
components of the case-control study: 1) identifying a sufficient number of IBC cases at the
time of diagnosis in the two study hospitals; 2) selecting appropriate hospital-based control
subjects; 3) collecting frozen pre-treatment tumor tissue; 4) obtaining digital photographs
of the breasts of IBC cases; and 5) communicating and working collaboratively with the study
hospitals and personnel in Egypt and Tunisia. To accomplish these objectives, IBC cases
meeting the AJCC definition as well as cases meeting other definitions of IBC will be
identified over a one-year period at each of the two study hospitals. Computerized records at
the control hospital for the years 2000-2003 will be used to enumerate the number of female
patients with non-chronic diseases (and their age and geographic distribution) in the
Departments of Ophthalmology and Ear, Nose and Throat (ENT). Pre-treatment frozen tumor
tissue and digital photographs of the breast will be collected from five IBC cases at each
study site.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05383196 -
Onvansertib + Paclitaxel In TNBC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02221999 -
Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients
|
Phase 2/Phase 3 | |
Completed |
NCT02324088 -
Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer
|
Phase 3 | |
Completed |
NCT00003199 -
Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
|
Phase 2 | |
Terminated |
NCT00016276 -
Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
|
Phase 3 | |
Recruiting |
NCT01880385 -
Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06131632 -
Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy
|
N/A | |
Completed |
NCT00513695 -
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
|
Phase 2 | |
Completed |
NCT00340158 -
Establishing an Inflammatory Breast Cancer Registry
|
N/A | |
Recruiting |
NCT04636710 -
Refining Local-Regional Therapy for IBC
|
N/A | |
Active, not recruiting |
NCT05415215 -
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
|
Phase 3 | |
Recruiting |
NCT04030507 -
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
|
N/A | |
Recruiting |
NCT03515798 -
Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer
|
Phase 2 | |
Completed |
NCT01583426 -
Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)
|
Phase 3 | |
Recruiting |
NCT02879513 -
Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy
|
Phase 3 | |
Completed |
NCT02199418 -
Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02623972 -
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
|
Phase 2 | |
Recruiting |
NCT00891280 -
Dose-escalation Study of Oral CX-4945
|
Phase 1 | |
Completed |
NCT00049114 -
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04660929 -
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
|
Phase 1 |